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Abstract
Background: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric
cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or
monitoring source for immune checkpoint inhibitor.
Methods: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood.
VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS).
Results: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes
with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs)
were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory
marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were
identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor,
VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like
group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid
was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group.
Conclusions: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC
can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC.
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Background
Gastric cancer ranks the fourth among the most common
cancers worldwide and the third in mortality rate [1]. It is
the second most common cancer in Korea. About 30,000
new cases are diagnosed in 1 year [2]. About 30~35% of
gastric cancer patients show initial distant metastasis.
Palliative chemotherapy is a standard treatment [3]. The
survival of patients with metastatic gastric cancer (mGC)
is less than 2 years. Anti-HER2 therapy with trastuzuamb
can prolong the survival of HER2 positive patients up to
13months [4, 5]. After the ToGA (Trastuzumab for Gas-
tric Cancer) study, the first positive study in advanced
gastric cancer using target agent, many studies have
attempted to find targeted therapy according to molecular
aberrations found in gastric cancer. Such studies are
supported by genetic profiling of tumor in several groups
including The Cancer Genome Atlas Research Network
(TCGA) [6]. After failure of several kinds of targeted
agents, immune checkpoint inhibitor (ICI) has emerged
as a new treatment option for gastric cancer. Nivolu-
mab and pembrolizumab have shown promising anti-
tumor activity [7, 8]. The biomarker of ICI is a major
issue in cancer field including metastatic gastric cancer.
It might help us better indicate which patients are most
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likely to have benefits [7, 9]. Several biomarkers such as
tumor mutation burden and programmed death-ligand
1 (PD-L1) status by immunohistochemistry (IHC) have
been suggested. However, none of them is considered as
a standard biomarker. The role of immune cells in
immune checkpoint inhibitor response is well known,
especially tumor infiltrating lymphocytes (TIL) in tumor
microenvironment. Thus, tumor can be categorized as
inflamed or non-inflamed. Inflamed tumor is characte-
rized by the presence of TIL, high density of CD8+ T cell,
and expression of PD-L1 in tumor or immune cells.
Collective clinical evidence suggests that ICI is more
effective for inflamed tumors [10].
However, not all patients with inflamed tumors respond
to ICI. T cell receptor (TCR)-peptide-major histocompati-
bility complex (pMHC) binding is the central event in the
activation of T cell. Activation antigens on T cell include
CD25, CD26, CD38, CD54, CD69, and HLA-DR [11, 12].
Activated T cells can trigger TME evolution including up-
regulation of inflammatory/suppressive cytokines, immune-
inhibitory cellular recruitment, and aberrant tumor vascula-
ture related to innate/acquired resistance. The complex
crosstalk among cancer cells, immune cells, and tumor
microenvironment is closely connected to each other.
Activation antigens on T cells could be detected according
to time. CD69 and CD25 are early antigens whereas HLA-
DR is a late marker [11]. The kinetics of expression of early
activation markers (CD69 and CD25) was similar to that of
PD-1 expression [13]. In tumor tissue, chronic exposure to
antigen and the development of dysfunctional or exhausted
effector T cell are accompanied by high expression of one
or more inhibitory receptors including PD-1, lymphocyte
activation gene 3 (LAG-3), and T-cell immunoglobulin and
mucin-domain containing-3 (TIM-3) [14]. In addition,
regulatory T cell and memory T cell play a role in the con-
trol of tumor growth and progression.
About 30–40% of mGC patients have malignant ascites
associated with peritoneal carcinomatosis [15, 16]. Ascites
has a different tumor microenvironment from primary
tumor, and it has high levels of immune suppressive
cytokines and immune cells [17–19]. Especially, several
cytokines such as VEGF-A, IL-10, and TGF-β1 have
immune suppressive function [20]. They are directly or
indirectly related to angiogenesis which has close inter-
action with immune cells for immune surveillance [21, 22].
The role and profile of these cytokines have been mostly
studied in ovarian cancer. Their expression level can affect
patient prognosis and drug resistance [23]. However, little
is known cytokines and immune signature in malignant
ascites of gastric cancer. Only a small number of studies
have dealt with this subject [20]. Ascites reflects tumor
microenvironment. It has advantage such as easier acquisi-
tion than tumor biopsy. Malignant ascites contains several
kinds of cytokines and plenty of immune cells having
directly contact with tumor cells, suggesting that malignant
ascites might serve as a good resource for immune moni-
toring of mGC patients. Therefore, the aim of this study
was to obtain profiles of cytokines and immune cells of
body fluid including ascites and pleural fluid in mGC and
evaluate their potential roles as prognostic factors. The
feasibility of using ascites as a predictive biomarker and a
monitoring source for immune checkpoint inhibitor was
also examined.
Methods
Study population
Between December 2014 and April 2016 at Yonsei Cancer
Center, Seoul, Korea, body fluid including ascites and
pleural fluid were obtained in a prospective, nonselective
fashion from 55 mGC patients via paracentesis or catheter
drainage. Twenty-four matched blood samples were also
taken before or at the time of body fluid acquisition.
Cancer cells from body fluid were confirmed by patholo-
gist using cell block. Eleven non-cancerous ascites and 4
matched blood samples were obtained from patients with
Child-Pugh B/C liver cirrhosis. Blood samples from 15
healthy volunteers were used as controls. Clinical data
including age and sex were collected for all study subjects.
The following clinico-pathologic information was ob-
tained by reviewing electronic medical records (EMR) of
gastric cancer (GC) patients: disease presentation (recur-
rent or metastatic), type of surgery, differentiation, Lauren
classification, HER2 status, type of body fluid, acquisition
timing of body fluid, and survival time. This study was
approved by the Institutional Review Board of Severance
Hospital (No. 4–2014-0638).
Measurement of immune suppressive cytokine
VEGF-A, IL-10, and TGF-β1 which are known immune
suppressive cytokines were selected for measurement to
evaluate their clinical roles and associations with immune
cells. Plasma was isolated from collected 10ml peripheral
blood in EDTA tube using Ficoll-Paque™ PLUS (GE
Healthcare, Sweden) gradient centrifugation and stored at
− 80 °C until assay. Body fluid was incubated in 10 X RBC
lysis buffer (Biolegend, CA, USA) to remove RBC and
centrifuged (5min, 1500 rpm). The supernatant was sepa-
rated, aliquoted, and stored at − 80 °C until analysis.
Plasma and body fluid supernatant were used to measure
levels of circulating VEGF-A, IL-10, and TGF-β1 using a
commercially available enzyme-linked immunosorbent
assay (ELISA) kit (Quantikine; R&D Systems Abingdon,
UK) following the manufacturer’s protocols. Samples were
measured in duplicates and mean value was presented as
final concentration. ELISA plates were read on a Sunrise
absorbance microplate reader (TECAN, Switzerland).
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Isolation of PBMC and lymphocyte in malignant fluid
Peripheral blood mononuclear cells (PBMCs) were isolated
from 10ml peripheral blood collected into EDTA tube
using Ficoll-Paque™ PLUS (GE Healthcare, Sweden) gradi-
ent centrifugation. Tumor associated lymphocytes (TALs)
from 100 to 500mL malignant fluid were isolated using
the following protocol. Briefly, the fluid was incubated with
10 X RBC lysis buffer (Biolegend, CA, USA) to remove
RBC and centrifuged in 50ml tubes at 1500 rpm for 5min.
After two washes with PBS (phosphate buffered saline),
isolated cells were suspended in 1ml of Cellbanker-2
(ZENOAQ, Japan) and stored at − 80 °C until analysis.
Flow cytometry and antibodies
Flow cytometry was performed using FACS LSR2 (BD Bio-
sciences, CA, USA). Data were analyzed using FlowJo soft-
ware (FlowJo, LLC, OR, USA). Fluorescence-conjugated
monoclonal antibodies were purchased from the following
sources: Human LAG-3 Alexa Fluor® 488-conjugated
Antibody (R&D system, MN, USA); PE/Cy7 anti-CD3,
FITC anti-CD4, PE anti-CD8, FITC anti-CD45RO, FITC
anti-HLA-DR, APC anti-CD25, APC/Cy7 anti-CD69, APC
anti-human CD279 (PD-1), APC/Cy7 anti-human CD366
(Tim-3), and PE anti-FoxP3 (BioLegend, CA, USA).
Furthermore, cells were stained with PE anti-human
CD274 (B7-H1, PD-L1, BioLegend, CA, USA) to identify
proportion of PD-L1 positive tumor cells in body fluid.
For Treg cell staining, cells were stained with various
antibodies except FoxP3 antibody for which cells were
fixed and permeabilized with eBioscience™ FoxP3
Fixation/Permeabilization solution (Thermo Fisher Scien-
tific, MA, USA). FoxP3 antibodies were administered after
permeabilization for intracellular staining of Tregs. FACS
analyses were performed for cells isolated from malignant
fluid and peripheral blood. First, levels of CD4+ and
CD25+ T cells in cells isolated from these two sources
(malignant fluid and peripheral blood) were measured.
Next, we quantified the percentage of cells that were
positive for FoxP3 in the CD4 + CD25+ T cell population.
Molecular subtype of primary tumor by histochemistry
Gastric cancer panel practically used in our institution has
10 markers, including Epstein-Barr virus encoded small
RNAs (EBER) in-situ hybridization, mismatch repair pro-
teins (MLH1, PMS2, MSH2, and MSH6), receptor tyrosine
kinases (RTKs; HER2, EGFR, and MET), PTEN, and p53
protein expression by IHC using formalin-fixed, paraffin-
embedded (FFPE) tissue blocks from paired primary sto-
mach cancer. Detailed methods of in situ hybridization
(ISH) and IHC staining have been described in our previous
study [24]. Patients were categorized by The Cancer
Genome Atlas (TCGA) molecular subtypes, including
Epstein Barr Virus (EBV) positive, microsatellite instability
(MSI), genomically stable (GS)-like, and chromosomal
instability (CIN)-like. CIN-like group patients had overex-
pression of HER2 (ISH 3+ or ISH2 +with amplification by
ISH), EGFR (2+ or 3+), MET (2+ or 3+), and PTEN loss.
Others with all markers negative were included in the GS-
like group. In landscape analysis, continuous variables were
expressed by categorized value (low vs. high group) which
was determined by the best cut off point.
Statistical analysis
Differences in cytokine and immune profiles among blood
and body fluid samples were compared using the Mann-
Whitney U test. Pearson’s correlation coefficient was calcu-
lated to determine relationships among variables. A value
of higher than 0.7 means highly positive correlation [25].
Continuous variable were transformed into categorical vari-
ables with high or low to calculate the maximizing hazard
ratio (HR) based on log-rank statistics presented by Contal
and O’Quigley [26]. The overall survival (OS) was defined
as the time from body fluid acquisition to death from any
cause. Time to event endpoint was analyzed by Kaplan-
Meier survival curves using the log-rank test. Scoring
system using ascites cytokines according to best-cut off
point was made to establish a prognostic model. A number
of cytokines with high expression levels including VEGF-A,
IL-10, and TGF-β1 were categorized as 0–1 and 2–3. To
determine independent prognostic factor, significant prog-
nostic factors identified in univariate analysis were analyzed
with multivariate Cox proportional hazard model using for-
ward stepwise analysis. A p-value of less than 0.05 was con-
sidered statistically significant. PASW Statistics 18.0 (SPSS
Inc. Chicago, IL, USA) was used for all statistical analyses.
Results
Patient characteristics
Baseline characteristics of enrolled patients are shown in
Table 1. The median age of 15 healthy volunteers was 63
years (range, 27–77 years) and eight (53%) were females.
Eleven Child-Pugh B/C liver cirrhosis patients with ascites
were enrolled as controls. Their median age was 53 years
(range, 35–79 years) and seven (63.6%) were males. Fifty-
five mGC patients with ascites or pleural fluid were
enrolled. Their median age was 58 years (range, 25–75).
There were 66% males. Fourteen (25%) patients had recur-
rent gastric cancer. Thirty-nine (71%) patients had poorly
differentiated or signet ring cell features. Eight (14.5%)
patients were HER2 positive. Forty-four (80%) patients
had palliative chemotherapy history at the time of body
fluid acquisition.
Comparison of immune suppressive cytokines in healthy
volunteers, liver cirrhosis patients, and gastric cancer
patients
Median values of plasma and body fluid cytokines are
shown in Additional file 1: Table S1. Plasma VEGF-A
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and IL-10 levels in mGC were significantly higher than
those in healthy volunteers (P = 0.013 and P = 0.001,
respectively). VEGF-A and IL-10 levels in mGC body
fluid were significantly higher than those in mGC
plasma and non-cancerous body fluid (Fig. 1a-b). In con-
trast, ascites TGF-β1 levels in liver cirrhosis samples
were lower than those in other samples, and remaining
samples showed no significant difference in TGF-β1
level among each other (Fig. 1c). When correlations of
cytokines between plasma and body fluid in mGC were
analyzed, levels of VEGF-A, but not those of IL-10 or
TGF-β1, showed significant correlations (P = 0.004,
correlation coefficient, r = 0.5647) (Additional file 4:
Figure S1). In addition, there were no significant correla-
tions among cytokines in body fluid (Additional file 5:
Figure S2).
Table 1 Baseline characteristics
No. %
Healthy volunteers (n = 15)
Age median, range 63 27-77
Sex Male 7 46.7
Female 8 53.3
Non-cancerous patients (n = 11)
Age median, range 53 35-79
Sex Male 7 63.6
Female 4 36.4
Gastric cancer patients (n = 55)
Age median, range 58 25-75
Sex Male 36 65.5
Female 19 34.5
Disease presentation Recurrent 14 25.5
Metastatic 41 74.5
Type of surgery Total gastrectomy 9 16.4
Subtotal gastrectomy 10 18.2
No 36 65.5
Differentiation WD 3 5.5
MD 9 16.4
PD 27 49.1
SRC 12 21.8
Othersa 4 7.3
Lauren Intestinal 7 12.7
Diffuse 10 18.2
Mixed 1 1.8
Unknown 37 67.3
HER2 Negative 46 83.6
Positive 8 14.5
Unknown 1 1.8
Type of body fluid Ascites 46 83.6
Pleural fluid 9 16.4
Previous palliative chemotherapy at acquisition of body fluid Chemotherapy-naïve 11 20.0
1 14 25.5
2 15 27.3
≥3 15 27.3
WD Well differentiated, MD Moderate differentiated, PD Poorly differentiated, SRC Signet ring cell carcinoma, No Number
Othersa: mucinous adenocarcinoma, undifferentiated carcinoma
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Immune cell profiling of paired PBMC and body fluid in
mGC
Results of immune cell profiling of peripheral blood and
body fluid in mGC are summarized in Additional file 2:
Table S2. Proportion of CD8/CD3 T cells showed a
higher tendency while CD4/CD8 ratio showed a lower
tendency in body fluid than those in peripheral blood
(P = 0.073 and P = 0.075, respectively) of mGC. Pro-
portion of memory T cell marked with CD45RO
(CD3CD45RO, CD4CD45RO and CD8CD45RO) and acti-
vated T lymphocytes (early activation marker CD3CD69,
CD4CD69, CD8CD69; late activation marker CD4HLA-
DR) were significantly higher in body fluid than those in
peripheral blood of mGC (Fig. 2a, b). In addition, T
lymphocytes with inhibitory marker including PD-1
(CD3PD1, CD4PD1 and CD8PD1) and number of
FoxP3+ T regulatory cells (Tregs) were significantly
higher in body fluid than those in peripheral blood
(Fig. 2c-d). Higher number of FoxP3+ Tregs in body fluid
was significantly associated with increased T cell with in-
hibitor marker such as LAG3 and TIM3 (Additional file 6:
Figure S3).
We then compared levels of cytokines and immune
cell profiling. VEGF-A and proportion of T cells with
CD69 or CD25 showed significant positive correlations
(CD3CD69, correlation coefficient, r = 0.377, P = 0.021;
CD4CD69, r = 0.374, P = 0.023; CD4CD25, r = 0.357,
P = 0.03; CD8CD25, r = 0.688, P < 0.001). In contrast,
VEGF-A and number of FoxP3+ Tregs showed
significant negative correlation (r = − 0.339, P = 0.043)
(Additional file 7: Figure S4), suggesting that increased
VEGF-A level might be related to immune suppressive
microenvironment.
Survival analysis for immune monitoring as a prognostic
factor
In survival analysis based on cytokines, high level of each
cytokine in body fluid (VEGF-A, IL-10, or TGF-β1)
showed poor survival outcome with borderline tendency
(Data not shown). However, patients with high levels of
at least two cytokines showed significantly shorter OS
than patients with zero or one cytokine at high level
(median OS, 1.6 vs. 2.2 months, P = 0.032, Fig. 3a-b).
Survival analysis was also conducted using immune cell
profiles. Results are shown in Fig. 3c-f. Higher proportions
of CD4/CD8 ratio, memory T cells (CD3CD45RO,
CD4CD45RO, CD8CD45RO), and T lymphocytes with ac-
tivation marker (CD3HLA-DR, CD4HLA-DR, CD8HLA-
DR, CD4CD25) or inhibitory marker (CD3PD1, CD8PD1)
were significantly associated with poor prognosis in uni-
variate analysis (Table 2 and Additional file 3: Table S3). In
multivariate analysis, proportion of CD8 T lymphocyte
with memory marker (CD8CD45RO) and late activation
marker (CD8HLA-DR), CD3 T lymphocyte with PD-1
(CD3PD1), number of FoxP3+ Tregs, and previous pallia-
tive chemotherapy history remained as independent
prognostic factors (Table 2).
Landscape analysis according to immune profile of body
fluid in each molecular subtype
Patients were classified by molecular subgroups of pri-
mary tumor. Patterns of cytokine and immune cell pro-
file from body fluid were compared with molecular
subgroups (Fig. 4). Only 1 patient was included in EBV
positive and MSI group, respectively. Thus, we focused
on CIN-like group (defined as those with overexpression
of RTKs) and GS-like group (defined as those who were
Fig. 1 Pro-angiogenic, immune modulatory cytokine, and immunosuppressive cytokines have different patterns in plasma and body fluid among
healthy volunteer, non-cancerous patients, and gastric cancer patients. a Plasma VEGF-A in mGC were significantly higher than those in healthy
volunteers (P = 0.013). VEGF-A levels in mGC body fluid were significantly higher than those in mGC plasma and non-cancerous body fluid. b
Plasma IL-10 levels in mGC were significantly higher than those in healthy volunteers (P = 0.001). IL-10 levels in mGC body fluid were significantly
higher than those in mGC plasma and non-cancerous body fluid (P = 0.014). c TGF-β1 levels in non-cancerous body fluid were significantly lower
than those in non-cancerous plasma (P = 0.005) and mGC body fluid. mGC, metastatic gastric cancer. Red line indicates median value. Mann-
Whitney U test was used for statistical analysis. *P < 0.05, **P < 0.01 ***P < 0.001
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negative for all markers including EBV, microsatellite,
and RTKs) to evaluate differences in cytokine and im-
mune profiling. VEGF-A level was significantly higher in
GS-like group than that in CIN-like group (median value:
163.9 vs. 17.4 pg/mL, P = 0.003). No significant difference
was observed in immune cell profile, although percentage
of PD-L1 positive tumor cells showed a higher tendency
in CIN-like group than that in GS-like group (median pro-
portion: 0.47 vs. 0.17%, P = 0.08) (Fig. 5a-b).
Dynamics of immune profile by chemotherapy
Cytokine and immune cell profile from body fluid were
compared between chemotherapy naïve and previously
treated groups. Proportion of early activated T cells
(CD3CD25 and CD4CD25) in previously chemotherapy
treated patients was higher level than that in chemo-
therapy naive patients (P = 0.017 and P = 0.035, respec-
tively, Fig. 5c-d). Fraction of memory T cell with
CD45RO showed higher tendency in chemotherapy
treated patients than that in chemotherapy naïve
patients (CD3CD45, P = 0.084; CD8CD45, P = 0.157). In
addition, body fluid of patients treated with chemothe-
rapy had higher VEGF-A levels than chemotherapy naïve
patients (median value, 59.7 vs. 31.4 pg/mL, P = 0.535),
suggesting that chemotherapy might induce immune
suppressive environment.
Discussion
Malignant body fluid of mGC has diverse cytokines and
immune cells which can represent tumor microenviron-
ment. It is relatively easy to access. In this study, immune
suppressive cytokines of malignant ascites were increased
compared to those of non-cancerous ascites. These
cytokines are significantly associated with diverse subsets
of immune cells. Immune cells with CD8CD45RO,
CD8HLA-DR, CD3PD1, and FoxP3+ Tregs had a prog-
nostic role in mGC. In addition, cytokine and immune cell
profiles of body fluid were different according to mole-
cular subtype of primary tumor and they can be changed
by cytotoxic chemotherapy.
As an extension of this study, in real-world practice,
angiogenesis inhibitor such as ramucirumab which had
inhibitory mechanism of interaction between VEGFR2
and VEGFs [27] could be preferred for mGC with higher
level of VEGF-A in malignant body fluid at any time point.
In addition, ICI could be given to patients with lower level
of VEGF-A (those of CIN-like group which had higher
percentage of PD-L1 positive tumor cells), despite the lack
of strong evidence. In the near future, biomarker studies
can be performed for mGC patients who have developed
malignant body fluid to evaluate the role of VEGF-A as a
predictive marker for angiogenesis inhibitor or immune
checkpoint inhibitor in randomized clinical trials.
Fig. 2 Proportion of immune cells were significantly higher in body fluid than those in peripheral blood. a Immune cell profiling of mGC body
fluid by FACS analysis were compared to those of mGC peripheral blood. Proportion of memory T cell marked with CD45RO (CD3CD45RO,
CD4CD45RO and CD8CD45RO) were significantly higher in body fluid than those in peripheral blood of mGC. b Activated T lymphocytes (early
activation marker CD3CD69, CD4CD69, CD8CD69) were significantly higher in body fluid than those in peripheral blood of mGC. c T lymphocytes
with inhibitory marker including PD-1 (CD3PD1, CD4PD1 and CD8PD1) were significantly higher in body fluid than those in peripheral blood. d
Number of FoxP3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in peripheral blood. mGC, metastatic gastric
cancer. Red line indicates median value. Mann-Whitney U test was used for statistical analysis. *P < 0.05, **P < 0.01 ***P < 0.001
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Tumor secrets various immune suppressive cytokines
such as VEGF, IL-6, and IL-10 to promote the accumula-
tion of heterogeneous populations of tumor associated
macrophages (TAMs), myeloid-derived suppressor cells
(MDSCs), and regulatory T cells [28]. VEGF-A, IL-10, and
TGF-β1 have been previously studied in metastatic ovar-
ian cancer patients with ascites. Most of these studies
showed that patients with higher levels of VEGF-A and
IL10 had adverse prognosis [19, 29]. Likewise, our study
showed that patients with higher levels of VEGF-A and
IL-10 had poor prognostic tendency. TGF-β1 of body fluid
was revealed as a poor prognostic factor in this study for
the first time. In addition, the lowest level of TGF-β1 was
observed in non-cancerous body fluid. This suggests that
TGF- β1 also has biological role in non-cancerous body
fluid. Using body fluid cytokines, we made a scoring
model to predict prognosis of patients with mGC, but it
should be validated by further studies.
Immune cell profiling of body fluid in mGC was also
conducted and compared to that of plasma. Proportion
of memory T cell with CD45RO and early activated T
cell with CD69 was higher in malignant body fluid than
that in plasma. This phenomenon was observed in other
studies on ovarian cancer [30]. It might be related to
malignant cells of body fluid that can induce immuno-
genicity. Proportions of suppressive T cell with PD-1
(CD3PD1, CD4PD1 and CD8PD1) and FoxP3+ Tregs
were also increased in malignant body fluid. The mech-
anism of these phenomena could not be explained
exactly. We can hypothesize that tumor cells in body
Fig. 3 Immune cytokines scoring model (patients were divided into two groups by number of high levels of three cytokines - VEGF-A, IL-10 and
TGF-β1, 0–1 vs. 2–3) from plasma and proportion of immune cells in malignant body fluid had a significant prognostic role in mGC. a Survival
analysis according to the number of high levels of cytokines did not meet the statistical significance for overall survival (P = 0.1). b Patients with
high levels of at least two cytokines showed significantly shorter OS than patients with zero or one cytokine at high level (median OS, 1.6 vs. 2.2
months, P = 0.032, c-e Patients with high proportion of CD8 T lymphocyte with memory marker (CD8CD45RO) and late activation marker
(CD8HLA-DR) and CD3 T lymphocyte with PD-1 (CD3PD1) were associated with poor prognosis. f Patients with high number of FoxP3+ cells
were significantly associated with favorable prognosis than mGC with low number of FoxP3+ cells in body fluid. mGC, metastatic gastric cancer.
Kaplan Meier survival analysis was performed for overall survival
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Table 2 Univariate analysis for overall survival
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age (years) < 58 years 1 0.913
≥58 years 1.03 0.57 1.86
Sex Male 1 0.831
Female 0.94 0.51 1.73
Disease presentation Recurrent 1 0.327
Metastatic 1.42 0.70 2.89
Differentiation WD 1 0.602
MD 4.94 0.61 39.76
PD 4.41 0.59 32.82
SRC 3.41 0.44 26.72
Others* 3.64 0.38 35.20
HER2 Negative 1 0.892
Positive 0.81 0.34 1.93
Palliative chemotherapy history No 1 0.003 1 0.005
Yes 4.19 1.63 10.78 10.78 2.05 56.81
Molecular subtype of primary tumor MSI 0.87 0.11 6.64 0.143
EBV 19.11 1.90 192.25
CIN-like 1.01 0.49 2.07
GS-like 1
Unknown 1.33 0.63 2.84
VEGF-A (pg/mL) < 100.9 pg/mL 1 0.127
≥100.9 pg/mL 1.58 0.88 2.86
IL-10 (pg/mL) > 243.8 pg/mL 1 0.16
≥243.8 pg/mL 1.64 0.82 3.25
TGF-β1 (pg/mL) < 393.6 pg/mL 1 0.197
≥393.6 pg/mL 1.97 0.70 5.55
Cytokine-scoring model 0–1 1 0.037
(number of high level of cytokines) 2–3 1.91 1.04 3.49
CD4/CD3 (%) < 41.7% 1 0.232
≥41.7% 0.65 0.32 1.32
CD8/CD3 (%) < 33.3% 1 0.272
≥33.3% 1.58 0.70 3.57
CD4/CD8 ratio < 0.6 1 0.034
≥0.6 0.35 0.13 0.92
CD8CD45RO+/CD8 (%) < 67.2% 1 0.021 1 0.019
≥67.2% 2.54 1.15 5.59 3.25 1.22 8.68
CD8CD25+/CD8 (%) < 1.6% 1 0.081
≥1.6% 1.92 0.92 3.99
CD8CD69+/CD8 (%) < 28.0% 1 0.054
≥28.0% 2.09 0.99 4.41
CD8HLA-DR+/CD8 (%) < 28.4% 1 0.008 1 0.012
≥28.4% 3.77 1.43 9.96 5.36 1.45 19.88
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fluid might induce body fluid to have an immune sup-
pressive status while activation marker is increased by
compensatory mechanism.
As a prognostic factor, higher proportions of
CD8CD45RO, CD8HLA-DR, and CD3PD1 were inde-
pendent poor prognostic factors. CD45RO and HLA-DR
are generally regarded as activation markers while PD1 is a
well-known suppressive marker [31, 32]. The number of
FoxP3+ Tregs was an independent prognostic factor in our
study, with higher number showing favorable prognostic
factor. Many studies have reported the role of FoxP3+
Tregs [33]. However, prognostic values of these cells in
cancer remain controversial. FoxP3+ Tregs are associated
with short survival in the majority of solid tumors inclu-
ding melanomas, cervical, renal, and breast cancers. In
contrast, FoxP3+ Tregs are associated with improved
survival in colorectal and esophageal cancer [33]. It has
been suggested that the role of FoxP3+ Tregs is influenced
by tumor sites, molecular subtypes, and tumor stage,
although related mechanisms are currently unknown.
Molecular subtype was classified into MSI, EBV, CIN-
like, and GS-like group based on immunohistochemistry
results, not genomics. Differences in cytokine and im-
mune profiling were clustered by each group. VEGF-A
level showed significant difference between CIN-like and
GS-like group. VEGF-A level was higher in the GS-like
group. However, other factors did not show statistically
significant differences between these two groups. CIN-like
group showed increased tendency of proportion of PD-L1
positive cancer cells than that in GS-like group. According
to these differences, anti-VEGF therapy might give GS-
like group more benefit while PD1 or PD-L1 inhibitor can
be applied to CIN-like group. However, further mecha-
nisms and clinical studies are needed to establish precision
medicine based on body fluid monitoring.
The benefit of immune monitoring has already been
studied and several approaches including tissue biopsy
and blood sampling are ongoing [10, 34, 35]. Body fluid
acquisition is more accessible than tissue. Thus, it is more
useful as a source of predictive marker. In addition, it can
be evaluated in real-time. To observe dynamics of cyto-
kines and immune profile, we evaluated differences in
cytokines and immune profile between chemotherapy
naïve and treated patients. Early activated T cell marked
with CD25 (CD3CD25, CD4CD25), memory T cell with
CD45RO, and VEGF-A were higher in previously chemo-
therapy treated group. Immune suppressive status after
chemotherapy can be assumed. By real-time monitoring
of the immune environment of patients, more effective
treatment strategy can be applied.
This study has some limitations. Firstly, a small number
of patients were analyzed. Therefore, it is hard to have
enough statistical power. Results of this study should be
validated through more studies with larger sample size.
Second, we only checked a limited number of cytokines
and immune cell markers. This should be overcome by
multiplex technology including cytometry by time of flight
(CyTOF). In addition, we did not perform comparison
between body fluid and tumor tissues due to invasiveness
of tumor biopsy and poor performance of most patients.
Table 2 Univariate analysis for overall survival (Continued)
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
CD8 TIM3+/CD8 (%) < 0.2% 1 0.082
≥0.2% 0.50 0.23 1.09
CD8 LAG3+/CD8 (%) < 3.7% 1 0.098
≥3.7% 1.92 0.89 4.17
CD8 PD1+/CD8 (%) < 50.2% 1 0.038
≥50.2% 2.58 1.06 6.31
CD3 PD1+/CD3 (%) < 17.2% 1 0.001 1 < 0.001
≥17.2% 3.53 1.66 7.52 8.61 2.81 26.37
CD4 PD1+/CD4 (%) < 32.1% 1 0.052
≥32.1% 2.11 0.99 4.50
FoxP3+ Tregs (No) < 380 1 0.029 1 0.001
≥380 0.40 0.18 0.91 0.13 0.04 0.42
PD-L1 positive tumor cells (%) < 1% 1 0.87
≥1% 1.07 0.49 2.34
VEGF vascular endothelial growth factor, IL interleukin, TGF-β1 transforming growth factor- beta1, CD cluster of differentiation, WD well differentiated, MD
moderate differentiated, PD poorly differentiated, SRC signet ring cell carcinoma, MSI microsatellite instability, EBV Epstein-Barr virus, CIN chromosomal instability,
GS genomically stable, HR hazard ratio, CI confidence interval, P p-value, No number
Others*: mucinous adenocarcinoma, undifferentiated carcinoma
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Fig. 4 Landscape shows the immune signature of body fluid in each molecular subtype of primary tissue. Patients were categorized by The
Cancer Genome Atlas (TCGA) molecular subtype which was composed of Epstein Barr Virus (EBV) positive, microsatellite instability (MSI),
genomically stable (GS)-like and chromosomal instability (CIN)-like. Diffuse type and intestinal type by Lauren classification were filled with yellow
and green, respectively. Molecular markers by histochemistry were classified with positive (red) or negative (orange). Continuous value of cytokine
and immune cell proportion were dichotomized by best-cut off which calculates the maximizing hazard ratio (HR) based on log-rank statistics
(low vs. high). Low value was filled with blue while high value was filled with pink. * Cytokine model was scored by a number of high levels of
VEGF-A, IL-10 and TGF-β1, and it was categorized 0–1 (low group) and 2–3 (high group). TCGA, The Cancer Genome Atlas; EBV, Epstein-Barr virus;
MSI-H, microsatellite instability-high; CIN, chromosomal instability; GS, genomically stable; VEGF, vascular endothelial growth factor; IL, interleukin;
TGF-β1, transforming growth factor- beta1; CD, cluster of differentiation
Fig. 5 VEGF-A and PD-L1 positivity on tumor cell (%) are different between CIN-like and GS-like group, and proportion of T lymphocyte with
CD25 is higher in previously chemotherapy treated group than chemotherapy naïve group. a VEGF-A level was significantly higher in GS-like
group than that in CIN-like group (median value: 163.9 vs. 17.4 pg/mL, P = 0.003). b PD-L1 (%) of tumor cells showed a higher tendency in CIN-
like group than that in GS-like group (median proportion: 0.47 vs. 0.17%, P = 0.08). c-d Proportion of early activated T cells (CD3CD25 and
CD4CD25) in previously chemotherapy treated patients was higher level than that in chemotherapy naive patients (P = 0.017 and P = 0.035,
respectively). Red line indicates median value. Mann-Whitney U test was used for statistical analysis. *P < 0.05, **P < 0.01
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However, this study also has several advantages. Healthy
volunteer and non-cancerous patients with ascites were
included as controls to find the distinct meaning of
immune profiling from malignant body fluid. In most
studies, characterization and prognostic role of malignant
body fluid were reported in ovarian cancer. Study of mGC
body fluid was limited. We comprehensively characterized
cytokines and immune profile of body fluid and evaluated
the possibility of using body fluid as a monitoring source
for predicting prognosis and marking therapeutic decision.
In addition, we checked the proportion of PD-L1 positive
tumor cells in body fluid. However, further studies with
serial sampling of body fluid acquisition and immune
profiling of paired primary tumor tissue are needed to
verify our results.
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